To give accurate information is our responsibly.
2026 is emerging as another important year for pharmaceutical innovation, with new therapies addressing obesity, cardiovascular disease, rare neurological disorders, cancer, infectious diseases, kidney disease …
FDA Drug Approvals 2026: Innovation Is Moving From Blockbusters to Precision Medicine, Oral Therapies and Rare Diseases The U.S. pharmaceutical industry has entered another important …
The obesity drug industry is entering a new phase of competition. The first wave was dominated by GLP-1 receptor agonists such as semaglutide, followed by …
China is becoming one of the most strategically important markets for antibody-drug conjugates (ADCs) as oncology treatment moves toward increasingly targeted therapies. A combination of …
India is entering a new phase of obesity and metabolic-disease treatment as GLP-1 drugs move from being primarily diabetes therapies to becoming an important part …
The global GLP-1 drugs market is rapidly transforming the pharmaceutical industry as demand increases for diabetes management, obesity treatment, and broader cardiometabolic care. According to …
The APAC point-of-care medical imaging market is entering an important phase of transformation as healthcare providers increasingly adopt portable, handheld, wireless and AI-enabled imaging technologies. …
The U.S. topical drugs landscape is entering a new phase of growth as pharmaceutical companies focus on targeted drug delivery, patient-friendly formulations, dermatology innovation, and …
A genetically engineered pig kidney has kept a kidney-failure patient off dialysis for approximately nine months, marking a major milestone for human xenotransplantation and strengthening …
Behavioral health and ABA clinics face a growing operational challenge: delivering quality care while managing increasingly complex administrative workflows. Insurance information, payer requirements, claims, documentation, …
by